Table: Sapporo Clinical Lab -2020/21 group results

Sapporo Clinical Laboratory

14/05/2021 07:30

May 14 (Reuters)- 
          Sapporo Clinical Laboratory Co Ltd 
          CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified)
                 Year ended      Year ended       Year to       NEXT   
              Mar 31, 2021    Mar 31, 2020   Mar 31, 2022     YEAR     
                 LATEST         YEAR-AGO        COMPANY      COMPANY   
                 RESULTS         RESULTS       FORECAST    H1 FORECAST 
  Sales           17.50           17.66          17.41         8.65    
               (-0.9 pct)      (+3.5 pct)     (-0.5 pct)    (+3.4 pct) 
  Operating        1.14          944 mln        855 mln      310 mln   
               (+20.9 pct)     (+15.9 pct)    (-25.1 pct)  (-15.7 pct) 
  Recurring        1.19          982 mln        957 mln      394 mln   
               (+20.9 pct)     (+20.9 pct)    (-19.4 pct)   (+4.7 pct) 
  Net
  Net            793 mln         528 mln        574 mln      200 mln   
               (+50.3 pct)     (+0.9 pct)     (-27.7 pct)  (-11.1 pct) 
  EPS          231.85 yen      154.30 yen     167.73 yen    58.55 yen  
  Ann Div       23.00 yen       10.00 yen      23.00 yen               
  -Q2 Div          NIL             NIL            NIL                  
  -Q4 Div       23.00 yen       10.00 yen      23.00 yen               
  
  NOTE - Sapporo Clinical Laboratory Co Ltd.
  *Second Net profit row denotes profit attributable to owners ofthe parent 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=9776.T